Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. more
Time Frame | SLN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -18.94% | 0.49% | -1.93% |
1-Month Return | -19.05% | -3.1% | -3.69% |
3-Month Return | -68.8% | -8.59% | 0.82% |
6-Month Return | -70.06% | -4.57% | 3.51% |
1-Year Return | -67.18% | -0.94% | 21.91% |
3-Year Return | -73.96% | 2.88% | 24.73% |
5-Year Return | -69.28% | 35.84% | 78.4% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 244.00K | 5.48M | 12.41M | 17.50M | 25.38M | [{"date":"2019-12-31","value":0.96,"profit":true},{"date":"2020-12-31","value":21.59,"profit":true},{"date":"2021-12-31","value":48.93,"profit":true},{"date":"2022-12-31","value":68.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | 3.76M | 7.46M | 10.88M | 10.32M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":34.58,"profit":true},{"date":"2021-12-31","value":68.53,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.83,"profit":true}] |
Gross Profit | 244.00K | 1.72M | 4.96M | 6.62M | 15.06M | [{"date":"2019-12-31","value":1.62,"profit":true},{"date":"2020-12-31","value":11.4,"profit":true},{"date":"2021-12-31","value":32.93,"profit":true},{"date":"2022-12-31","value":43.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 31.34% | 39.94% | 37.83% | 59.34% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":31.34,"profit":true},{"date":"2021-12-31","value":39.94,"profit":true},{"date":"2022-12-31","value":37.83,"profit":true},{"date":"2023-12-31","value":59.34,"profit":true}] |
Operating Expenses | 22.98M | 37.56M | 50.77M | 55.21M | 64.66M | [{"date":"2019-12-31","value":35.54,"profit":true},{"date":"2020-12-31","value":58.09,"profit":true},{"date":"2021-12-31","value":78.52,"profit":true},{"date":"2022-12-31","value":85.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (22.73M) | (35.85M) | (45.81M) | (48.59M) | (49.60M) | [{"date":"2019-12-31","value":-2273400000,"profit":false},{"date":"2020-12-31","value":-3584700000,"profit":false},{"date":"2021-12-31","value":-4581400000,"profit":false},{"date":"2022-12-31","value":-4859300000,"profit":false},{"date":"2023-12-31","value":-4960400000,"profit":false}] |
Total Non-Operating Income/Expense | (142.00K) | 1.53M | (40.00K) | 1.40M | 706.00K | [{"date":"2019-12-31","value":-9.26,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2.61,"profit":false},{"date":"2022-12-31","value":91.53,"profit":true},{"date":"2023-12-31","value":46.02,"profit":true}] |
Pre-Tax Income | (22.87M) | (36.04M) | (45.86M) | (47.37M) | (50.31M) | [{"date":"2019-12-31","value":-2287000000,"profit":false},{"date":"2020-12-31","value":-3604100000,"profit":false},{"date":"2021-12-31","value":-4585600000,"profit":false},{"date":"2022-12-31","value":-4736800000,"profit":false},{"date":"2023-12-31","value":-5031000000,"profit":false}] |
Income Taxes | (3.29M) | (3.49M) | (6.45M) | (6.88M) | (7.04M) | [{"date":"2019-12-31","value":-328800000,"profit":false},{"date":"2020-12-31","value":-349400000,"profit":false},{"date":"2021-12-31","value":-644600000,"profit":false},{"date":"2022-12-31","value":-687900000,"profit":false},{"date":"2023-12-31","value":-704300000,"profit":false}] |
Income After Taxes | (19.58M) | (32.55M) | (39.41M) | (40.49M) | (43.27M) | [{"date":"2019-12-31","value":-1958200000,"profit":false},{"date":"2020-12-31","value":-3254700000,"profit":false},{"date":"2021-12-31","value":-3941000000,"profit":false},{"date":"2022-12-31","value":-4048900000,"profit":false},{"date":"2023-12-31","value":-4326700000,"profit":false}] |
Income From Continuous Operations | (19.58M) | (22.06M) | (39.41M) | (40.49M) | (43.27M) | [{"date":"2019-12-31","value":-1958200000,"profit":false},{"date":"2020-12-31","value":-2205800000,"profit":false},{"date":"2021-12-31","value":-3941000000,"profit":false},{"date":"2022-12-31","value":-4048900000,"profit":false},{"date":"2023-12-31","value":-4326700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.58M) | (32.55M) | (39.41M) | (40.49M) | (43.27M) | [{"date":"2019-12-31","value":-1958200000,"profit":false},{"date":"2020-12-31","value":-3254700000,"profit":false},{"date":"2021-12-31","value":-3941000000,"profit":false},{"date":"2022-12-31","value":-4048900000,"profit":false},{"date":"2023-12-31","value":-4326700000,"profit":false}] |
EPS (Diluted) | (0.34) | (0.56) | (1.16) | 0.11 | (0.76) | [{"date":"2019-12-31","value":-307.83,"profit":false},{"date":"2020-12-31","value":-504.86,"profit":false},{"date":"2021-12-31","value":-1044.28,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-685.96,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SLN | |
---|---|
Cash Ratio | 7.63 |
Current Ratio | 9.31 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SLN | |
---|---|
ROA (LTM) | -21.54% |
ROE (LTM) | -64.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SLN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.44 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.56 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SLN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 15.80 |
P/B | 2.43 |
Price/FCF | NM |
EV/R | 3.66 |
EV/Ebitda | NM |
Silence Therapeutics PLC (SLN) share price today is $5.889
Yes, Indians can buy shares of Silence Therapeutics PLC (SLN) on Vested. To buy Silence Therapeutics PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Silence Therapeutics PLC (SLN) via the Vested app. You can start investing in Silence Therapeutics PLC (SLN) with a minimum investment of $1.
You can invest in shares of Silence Therapeutics PLC (SLN) via Vested in three simple steps:
The 52-week high price of Silence Therapeutics PLC (SLN) is $27.72. The 52-week low price of Silence Therapeutics PLC (SLN) is $5.81.
The price-to-earnings (P/E) ratio of Silence Therapeutics PLC (SLN) is
The price-to-book (P/B) ratio of Silence Therapeutics PLC (SLN) is 2.43
The dividend yield of Silence Therapeutics PLC (SLN) is 0.00%
The market capitalization of Silence Therapeutics PLC (SLN) is $271.96M
The stock symbol (or ticker) of Silence Therapeutics PLC is SLN